Drug intelligence / Profile preview

RT1003

Development stage: Preclinical
Lead developer: Jiangsu Rongtai Biotech
Modality: Small Molecules

Overview

RT1003 is a preclinical-stage drug candidate being developed by Jiangsu Rongtai Biotech (also known as JSRT Biotech) for the treatment of pain. As an analgesic in the early stages of the drug development pipeline, specific details regarding its chemical structure, molecular target, and pharmacological profile have not been publicly released. The compound represents part of the company's efforts to develop novel therapeutics for pain management, likely utilizing small molecule chemistry based on the developer's primary focus on innovative chemical drug synthesis.

Targets

GLP1R (GLP-1R)

Beyond the preview

Go deeper on RT1003.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RT1003.

Explore the full profile